Lexaria Bioscience (LEXX) Accumulated Expenses (2019 - 2022)
Lexaria Bioscience's (LEXX) quarterly Accumulated Expenses came in at $6884.0 in Q1 2022, down 97.94% quarter-over-quarter from $334523.0 in Q1 2019.
Lexaria Bioscience (LEXX) Accumulated Expenses (2019 - 2022) Analysis & Trends
Lexaria Bioscience has disclosed Accumulated Expenses across 2 years of filings, most recently posting $6884.0 for Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Lexaria Bioscience | 7.17 Mn | 1.65 Mn | 20,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2022 | 6,884.00 |
| Feb 28, 2019 | 334,523.00 |